Landscapes / Targets
TTR
8 drugs act on TTR, in 19 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs8
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Transthyretin stabilizer |
Approved in the EU | 17 Sep 2027Phase 4 trial completes | |||
| Next date | 17 Sep 2027 · Phase 4 trial completes | ||||
| Also tested for | Transthyretin Amyloid Cardiomyopathy | ||||
| Open drug page | |||||
Small interfering RNA |
Alnylam · Public ALNY |
Approved | 27 Dec 2027Phase 3 trial completes | ||
| How it works | A short strand of RNA that switches off one gene | ||||
| Next date | 27 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy and 1 more | ||||
| Open drug page | |||||
Transthyretin stabilizer |
Approved in Japan | 31 Mar 2028Phase 4 trial completes | |||
| Next date | 31 Mar 2028 · Phase 4 trial completes | ||||
| Also tested for | Transthyretin-type Cardiac Amyloidosis | ||||
| Open drug page | |||||
Transthyretin stabilizer |
Approved | 15 Apr 2028Phase 3 trial completes | |||
| Next date | 15 Apr 2028 · Phase 3 trial completes | ||||
| Also tested for | Amyloidosis, Amyloid Cardiomyopathy and 11 more | ||||
| Open drug page | |||||
Transthyretin-directed RNA Interaction; antisense oligonucleotide |
Ionis Pharmaceuticals +1 · Public AZN |
Approved | 6 Feb 2029Phase 2 trial completes | ||
| How it works | A short strand of genetic material that blocks one gene's message | ||||
| Next date | 6 Feb 2029 · Phase 2 trial completes | ||||
| Also tested for | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy, Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) and 2 more | ||||
| Open drug page | |||||
— |
Phase 3 | Jul 2027Phase 3 trial completes | |||
| Next date | Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, Neuromuscular Disease and 19 more | ||||
| Open drug page | |||||
— |
Phase 3 | 6 Dec 2027Phase 3 trial completes | |||
| Next date | 6 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Transthyretin Amyloid Cardiomyopathy and 1 more | ||||
| Open drug page | |||||
Small interfering RNA |
Alnylam · Public ALNY |
Phase 3 | 27 Dec 2027Phase 3 trial completes | ||
| How it works | A short strand of RNA that switches off one gene | ||||
| Next date | 27 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Transthyretin Amyloidosis With Cardiomyopathy, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 8 of 8 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026